{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 6:', 'Prohibited QTc-Prolonging Drugs', 'Generic', 'Class/clinical use', 'Note', 'Azithromycin', 'Antibiotic/bacterial infection', 'Chloroquine/Mefloquine', 'Anti-malarial/malaria infection', 'Clarithromycinb', 'Antibiotic/bacterial infection', 'Domperidone', 'Anti-nausea/nausea', 'Not available in the USA', 'Droperidol', 'Sedative; anti-nausea/anesthesia adjunct, nausea', 'Erythromycinb', 'Antibiotic; GI stimulant; GI motility', 'Moxifloxacin', 'Antibiotic/bacterial infection', 'Sevoflurane', 'Anesthetic, general/anesthesia', 'Probucol', 'Antilipemic/hypercholesterolemia', 'Not available in the USA', 'Sparfloxacin', 'Antibiotic/bacterial infection', 'Not available in the USA', 'a', 'Patients are allowed to take up 500 mg/day of azithromycin.', 'b', 'Systemic use only. Topical use is allowed.', 'Gl=gastrointestinal; QTc=corrected QT; USA=United States of America.', 'Table 7:', 'Prohibited Antipsychotic Drugs', 'Typical/first generation antipsychotics', 'Atypical/second generation antipsychotics', 'Chlorpromazine', 'Aripiprazole', 'Haloperidol', 'Asenapine maleate', 'Loxapine', 'Clozapine', 'Molindone', 'Iloperidone', 'Perphenazine', 'Lurasidone', 'Pimozide', 'Olanzapine', 'Prochlorperazine', 'Olanzapine/fluoxetine', 'Thioridazine', 'Paliperidone', '207']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Thiothixene', 'Quetiapine', 'Trifluoperazine', 'Risperidone', 'Promethazine-containing compounds', 'Ziprasidone', 'Fluphenazine', 'Tiapride', 'Note: This table does not apply in the second week of washout for patients not rolling over to the open-label extension study (Study', 'TV50717-CNS-30047).', 'Table 8:', 'Other Prohibited Drugs', 'Generic', 'Class/clinical use', 'Note', 'Cannabidiol oil', 'Cannabis', 'Also includes other forms of', 'cannabinoids', 'Valbenazine', 'Vesicular monoamine transporter 2 inhibitor', 'Ingrezza off-label', 'Quinidine', 'Class I antiarrhythmic agent', 'Strong CYP2D6 inhibitor', 'Terbinafine', 'Antifungal medication', 'Weak CYP2D6 inhibitor', '208']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX B. DISTRIBUTION OF AUC BY WEIGHT CATEGORIES AND CYP2D6 STATUS', 'Figure 2:', 'Distribution of AUC of Total (a+B)-HTBZ for Selected Doses Based on Weight Categories', 'Functional CYP2D6', 'Impaired CYP2D6', '15 mg bid', '21 mg bid', '24 mg bid', '24 mg bid', '9 mg bid', '(non-impaired)', '12 mg bid', '18 mg bid', '24 mg bid', '(non impaired)', '5000', '5000', '4000', '4000', '3000', '3000', '2000', '2000', '1000', '1000', 'Weight Group', 'Weight Group', 'AUC=area under the curve; CYP2D6=cytochrome P450 2D6; a/\u00df-HTBZ=alpha/beta-dihydrotetrabenazine', '209']\n\n###\n\n", "completion": "END"}